dc.contributor.author
Seidensticker, Max
dc.contributor.author
Seidensticker, Ricarda
dc.contributor.author
Damm, Robert
dc.contributor.author
Mohnike, Konrad
dc.contributor.author
Pech, Maciej
dc.contributor.author
Sangro, Bruno
dc.contributor.author
Hass, Peter
dc.contributor.author
Wust, Peter
dc.contributor.author
Kropf, Siegfried
dc.contributor.author
Gademann, Günther
dc.contributor.author
Ricke, Jens
dc.date.accessioned
2018-06-08T03:13:58Z
dc.date.available
2015-02-19T13:05:16.637Z
dc.identifier.uri
https://refubium.fu-berlin.de/handle/fub188/14744
dc.identifier.uri
http://dx.doi.org/10.17169/refubium-18934
dc.description.abstract
Background/Aim Targeted radiotherapy of liver malignancies has found to be
effective in selected patients. A key limiting factor of these therapies is
the relatively low tolerance of the liver parenchyma to radiation. We sought
to assess the preventive effects of a combined regimen of pentoxifylline
(PTX), ursodeoxycholic acid (UDCA) and low-dose low molecular weight heparin
(LMWH) on focal radiation-induced liver injury (fRILI). Methods and Materials
Patients with liver metastases from colorectal carcinoma who were scheduled
for local ablation by radiotherapy (image-guided high-dose-rate interstitial
brachytherapy) were prospectively randomized to receive PTX, UDCA and LMWH for
8 weeks (treatment) or no medication (control). Focal RILI at follow-up was
assessed using functional hepatobiliary magnetic resonance imaging (MRI). A
minimal threshold dose, i.e. the dose to which the outer rim of the fRILI was
formerly exposed to, was quantified by merging MRI and dosimetry data. Results
Results from an intended interim-analysis made a premature termination
necessary. Twenty-two patients were included in the per-protocol analysis.
Minimal mean hepatic threshold dose 6 weeks after radiotherapy (primary
endpoint) was significantly higher in the study treatment-group compared with
the control (19.1 Gy versus 14.6 Gy, p = 0.011). Qualitative evidence of fRILI
by MRI at 6 weeks was observed in 45.5% of patients in the treatment versus
90.9% of the control group. No significant differences between the groups were
observed at the 12-week follow-up. Conclusions The post-therapeutic
application of PTX, UDCA and low-dose LMWH significantly reduced the extent
and incidence fRILI at 6 weeks after radiotherapy. The development of
subsequent fRILI at 12 weeks (4 weeks after cessation of PTX, UDCA and LMWH
during weeks 1–8) in the treatment group was comparable to the control group
thus supporting the observation that the agents mitigated fRILI.
en
dc.rights.uri
http://creativecommons.org/licenses/by/4.0/
dc.subject.ddc
600 Technik, Medizin, angewandte Wissenschaften::610 Medizin und Gesundheit::615 Pharmakologie, Therapeutik
dc.title
Prospective Randomized Trial of Enoxaparin, Pentoxifylline and Ursodeoxycholic
Acid for Prevention of Radiation-Induced Liver Toxicity
dc.type
Wissenschaftlicher Artikel
dcterms.bibliographicCitation
PLoS ONE. - 9 (2014), 11, Artikel Nr. e112731
dcterms.bibliographicCitation.doi
10.1371/journal.pone.0112731
dcterms.bibliographicCitation.url
http://journals.plos.org/plosone/article?id=10.1371/journal.pone.0112731
refubium.affiliation
Charité - Universitätsmedizin Berlin
de
refubium.mycore.fudocsId
FUDOCS_document_000000021884
refubium.note.author
Der Artikel wurde in einer Open-Access-Zeitschrift publiziert.
refubium.resourceType.isindependentpub
no
refubium.mycore.derivateId
FUDOCS_derivate_000000004566
dcterms.accessRights.openaire
open access